King Faisal Specialist Hospital, Riyadh – United Arab Emirates
About Dr. Abdulrahman Almusa, MD
Dr. Abdulrahman Almusa is a Consultant in Pediatric Hematology/Oncology specialising in non-malignant blood disorders, haemophilia, von Willebrand disease, and paediatric myeloproliferative disorders for international families seeking expert pediatric hematology specialist care in Riyadh, Saudi Arabia. He is a principal investigator on national research into paediatric bleeding disorders and thrombocythaemia.
- Consultant specialising in paediatric non-malignant blood disorders and bleeding diatheses
- Principal Investigator on landmark 30-year pediatric essential thrombocythaemia study
- Contributor to national hemophilia screening and inhibitor surveillance programmes
- Published author on paediatric von Willebrand disease (189-patient cohort study)
- Active in paediatric stem cell transplantation for non-malignant disorders
Qualifications & Credentials
Medical Degrees
- MBBS, MD — Bachelor of Medicine and Bachelor of Surgery
- Pediatrics Residency
Fellowships & Special Training
- Fellowship — Pediatric Hematology/Oncology
- Advanced training in Non-Malignant Blood Disorders
Certifications & Accreditations
- Saudi Commission for Health Specialties (SCFHS) — Consultant
Areas of Expertise
Major Conditions Treated
- Haemophilia A and B
- Von Willebrand Disease
- Factor VIII and IX Inhibitor-Related Bleeding
- Paediatric Essential Thrombocythaemia
- β-Thalassaemia Major
- Sickle Cell Disease
- Aplastic Anaemia (Paediatric)
- Immune Thrombocytopaenia (ITP)
- Myeloproliferative Neoplasms (Paediatric)
- Acute Leukaemia (Paediatric)
- Bone Marrow Failure Syndromes
Sub-specialties
- Pediatric Bleeding Disorders: Expert management of haemophilia, von Willebrand disease, and rare congenital bleeding disorders — a trusted pediatric hematologist in Riyadh for international families seeking best pediatric blood disorder care in Saudi Arabia.
- Paediatric Myeloproliferative Disorders: Management of paediatric essential thrombocythaemia and related rare MPNs, including JAK2 mutation testing and long-term follow-up.
- Haemoglobinopathies: Comprehensive care for thalassaemia and sickle cell disease including transfusion therapy and transplant evaluation.
Advanced Procedures & Treatments
- Factor Replacement Therapy (FVIII, FIX, vWF concentrates)
- Inhibitor Eradication (Immune Tolerance Induction)
- Transfusion Therapy and Iron Chelation
- JAK2 V617F Mutation Testing and Interpretation
- Paediatric Allogeneic HSCT (in collaboration with transplant team)
- Bone Marrow Biopsy and Aspiration
- Platelet Function Testing
Professional Experience
Current Affiliation
- King Faisal Specialist Hospital & Research Centre (KFSHRC), Riyadh — Consultant, Pediatric Hematology/Oncology, Department of Pediatric Hematology/Oncology (Present)
Academic & Research Roles
- Principal Investigator — Paediatric Essential Thrombocythaemia Study at KFSHRC
- Co-investigator — Saudi National Hemophilia Inhibitor Screening Program
- Faculty — Pediatric Hematology/Oncology Fellowship Program, KFSHRC
Key Achievements
- Principal Investigator on 30-year retrospective study of paediatric essential thrombocythaemia
- Co-author of Saudi National Hemophilia Screening Program findings
- Contributor to 189-patient von Willebrand disease clinical and laboratory cohort study
- Experienced in treating international paediatric haematology patients from GCC, Africa, and South Asia
Awards & Recognitions
National & International Awards
- Information not publicly available.
Professional Memberships
- Saudi Arabian Pediatric Hematology Oncology Society (SAPHOS)
- Saudi Society of Hematology
Research & Publications
Published Papers (Selected)
- Ameen M, Siddiqui K, Khan S, Saleh M, Al-Jefri A, Al-Musa A. "Essential Thrombocythemia in Children: A Retrospective Study." Journal of Hematology. 2021. DOI: 10.14740/jh822.
- Owaidah T, Al Momen A, Alzahrani H, Almusa A, et al. "The prevalence of factor VIII and IX inhibitors among Saudi patients with hemophilia: Results from the Saudi national hemophilia screening program." Medicine (Baltimore). 2017. PMC5266150.
- Owaidah T, Almusa A, Alnouno R, Alzahrani H, et al. "Clinical and laboratory presentation of von Willebrand disease: Experience from a single center in Saudi Arabia." 2023 Apr. PMC10124135.
- AlJefri A, ..., Al-Musa A, Ayas M. "Successful Second Hematopoietic Stem Transplantation Using TBI-Based Conditioning for Children with Transfusion-Dependent β-Thalassemia." Transplantation and Cellular Therapy. 2025.
Ongoing Research & Clinical Interests
- Paediatric bleeding disorders and inhibitor management
- Essential thrombocythaemia outcomes in children
- Von Willebrand disease clinical presentation and outcomes
- Non-malignant paediatric blood disorders requiring transplantation
Estimated Treatment Costs
| Procedure / Consultation | Estimated Cost (INR) | Estimated Cost (USD) |
|---|---|---|
| Pediatric Hematology Consultation | ₹2,000 – ₹5,000 | $25 – $60 |
| Factor VIII / IX Concentrate (per infusion) | ₹30,000 – ₹1,00,000 | $360 – $1,200 |
| Immune Tolerance Induction Therapy | ₹5,00,000 – ₹20,00,000 | $6,000 – $24,000 |
| Pediatric Bone Marrow Biopsy | ₹10,000 – ₹25,000 | $120 – $300 |
| Iron Chelation Therapy (monthly) | ₹15,000 – ₹50,000 | $180 – $600 |
| Allogeneic HSCT (pediatric, non-malignant) | ₹20,00,000 – ₹40,00,000 | $24,000 – $48,000 |
*Indicative estimates only. Actual costs subject to hospital pricing, case complexity, and insurance. Contact Cancer Rounds for a personalised quote.
Frequently Asked Questions
1. What advanced technologies does Dr. Abdulrahman Almusa use in Pediatric Hematology / Oncology treatment?
Dr. Abdulrahman Almusa uses factor replacement therapy, immune tolerance induction for inhibitor-positive haemophilia, JAK2 mutation testing, advanced coagulation laboratory diagnostics, platelet function assays, and multidisciplinary stem cell transplant evaluation. Virtual consultations are available for international paediatric patients. Contact Cancer Rounds for a detailed technology overview.
2. What conditions does Dr. Abdulrahman Almusa specialize in treating?
Dr. Abdulrahman Almusa specialises in non-malignant paediatric blood disorders including haemophilia A and B, von Willebrand disease, factor inhibitors, essential thrombocythaemia, β-thalassaemia, sickle cell disease, aplastic anaemia, and immune thrombocytopaenia. International families seek his expertise as a pediatric hematologist in Riyadh, Saudi Arabia.
3. How do I book an appointment with Dr. Abdulrahman Almusa?
Appointments with Dr. Abdulrahman Almusa can be booked directly through the Cancer Rounds website or by contacting their international patient department for priority scheduling.
4. Can international patients receive treatment from Dr. Abdulrahman Almusa?
Yes. Cancer Rounds provides full assistance for international patients seeking treatment from Dr. Abdulrahman Almusa, including medical visa invitation letters, airport transfers, and local accommodation coordination.
5. What support is available for international patients?
International patients benefit from a dedicated concierge service provided by Cancer Rounds, including language interpretation, financial counselling, and pre-travel virtual consultations to review medical records before arrival.
6. Does Dr. Abdulrahman Almusa offer second opinions for Pediatric Hematology / Oncology cases?
Yes. Second opinion consultations for Pediatric Hematology / Oncology can be arranged via Cancer Rounds for families who wish to review their child's diagnosis or treatment plan with an expert pediatric hematologist in Riyadh, Saudi Arabia.
